{
    "nct_id": "NCT06625320",
    "official_title": "RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)",
    "inclusion_criteria": "* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed PDAC with metastatic disease.\n* Measurable disease per RECIST 1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation)\n* Documented RAS mutation status, either mutant or wild-type. Eligible RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).\n* Able to take oral medications.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).\n* History of or known central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study treatment\n* Major surgery within 4 weeks prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures",
    "miscellaneous_criteria": ""
}